Allogene Therapeutics, Inc. generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior fiscal year. The table below carries 8 fiscal years, from 2018 to 2025, and the quarters Allogene Therapeutics, Inc. has filed alongside them.

Annual figures, oldest first. Point at a bar to read its period.

ALLO Revenue by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Revenue	$0-100.0%	$22K-76.8%	$95K-39.1%	$156K-99.9%	$114.1M	$0	$0	N/A

ALLO Revenue by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q
Revenue	$4.6M	N/A	N/A	$0	$0	$0-100.0%	N/A	$0-100.0%	$0-100.0%	$22K-26.7%	$21K-19.2%	$22K-18.5%

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Allogene Therapeutics, Inc. financials

• Every ALLO statement on one page
• ALLO Net Income
• ALLO EPS (Diluted)
• ALLO Free Cash Flow
• ALLO Debt & Cash
• ALLO Balance Sheet

Frequently Asked Questions

What was Allogene Therapeutics, Inc.'s revenue in fiscal year 2025?

Allogene Therapeutics, Inc. generated $0 in revenue in fiscal year 2025.

How fast is Allogene Therapeutics, Inc.'s revenue growing?

Allogene Therapeutics, Inc. (ALLO) revenue fell by 100.0% year over year, from $22K to $0 in fiscal year 2025.

What was Allogene Therapeutics, Inc.'s revenue in the most recent quarter?

Allogene Therapeutics, Inc. (ALLO) reported $4.6M in revenue in Q2 2026.

What does revenue mean on a financial statement?

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Allogene Therapeutics, Inc. (ALLO) reported on that line in every period on record.